U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C20H30NO3
Molecular Weight 332.4571
Optical Activity ( + / - )
Defined Stereocenters 4 / 5
E/Z Centers 0
Charge 1

SHOW SMILES / InChI
Structure of IPRATROPIUM

SMILES

CC(C)[N@+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)C3=CC=CC=C3

InChI

InChIKey=OEXHQOGQTVQTAT-VQCHGODESA-N
InChI=1S/C20H30NO3/c1-14(2)21(3)16-9-10-17(21)12-18(11-16)24-20(23)19(13-22)15-7-5-4-6-8-15/h4-8,14,16-19,22H,9-13H2,1-3H3/q+1/t16-,17+,18+,19-,21?/m0/s1

HIDE SMILES / InChI
Molecular Formula C20H29NO3
Molecular Weight 331.4492
Charge 0
Count
Stereochemistry EPIMERIC
Additional Stereochemistry No
Defined Stereocenters 4 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68009241

Ipratropium (ipratropium bromide, ATROVENT® HFA) is a muscarinic antagonist structurally related to atropine but often considered safer and more effective for inhalation use. It is indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Ipratropium (ipratropium bromide, ATROVENT® HFA) is an anticholinergic (parasympatholytic) agent which, based on animal studies, appears to inhibit vagally-mediated reflexes by antagonizing the action of acetylcholine, the transmitter agent released at the neuromuscular junctions in the lung. Anticholinergics prevent the increases in intracellular concentration of Ca2+ which is caused by interaction of acetylcholine with the muscarinic receptors on bronchial smooth muscle.

CNS Activity

CNS Penetrant
2554
Curator's Comment: Raeburn, David, Giembycz, Mark A. (2012). Rhinitis: Immunopathology and Pharmacotherapy. Springer. p. 133: "Topical intranasal ipratropium bromide has limited central nervous system penetration".

Originator

Boehringer Ingelheim
131
Sources: Svenska lakartidningen (1962), 59, 3384-5.
Curator's Comment: Ravina, Enrique (2011). The evolution of drug discovery: from traditional medicines to modern drugs (1. Aufl. ed.). Weinheim: Wiley-VCH. p. 144.

Approval Year

1986
103
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2778
 0.49 nM [Ki]
Antagonist
2778
 1.5 nM [Ki]
Antagonist
2778
 0.51 nM [Ki]
Antagonist
2778
 0.66 nM [Ki]
Antagonist
2778
 1.7 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
ATROVENT HFA

Approved Use

ATROVENT HFA Inhalation Aerosol is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Launch Date

1.10142725E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
33.5 pg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021747s010lbl.pdf
20 μg 4 times / day multiple, respiratory
dose: 20 μg
route of administration: Respiratory
experiment type: MULTIPLE
co-administered: ALBUTEROL
ALBUTEROL
 IPRATROPIUM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
31.7 pg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021747s010lbl.pdf
20 μg 4 times / day steady-state, respiratory
dose: 20 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered: ALBUTEROL
ALBUTEROL
 IPRATROPIUM plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE
food status: UNKNOWN
35.4 pg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021747s010lbl.pdf
20 μg 4 times / day steady-state, respiratory
dose: 20 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered: ALBUTEROL
ALBUTEROL
 IPRATROPIUM plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1.04 pg × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021747s010lbl.pdf
20 μg 4 times / day multiple, respiratory
dose: 20 μg
route of administration: Respiratory
experiment type: MULTIPLE
co-administered: ALBUTEROL
ALBUTEROL
 IPRATROPIUM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
123 pg × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021747s010lbl.pdf
20 μg 4 times / day steady-state, respiratory
dose: 20 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered: ALBUTEROL
ALBUTEROL
 IPRATROPIUM plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE
food status: UNKNOWN
131 pg × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021747s010lbl.pdf
20 μg 4 times / day steady-state, respiratory
dose: 20 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered: ALBUTEROL
ALBUTEROL
 IPRATROPIUM plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021747s010lbl.pdf
20 μg 4 times / day multiple, respiratory
dose: 20 μg
route of administration: Respiratory
experiment type: MULTIPLE
co-administered: ALBUTEROL
ALBUTEROL
 IPRATROPIUM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
95.5%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021747s010lbl.pdf
20 μg 4 times / day multiple, respiratory
dose: 20 μg
route of administration: Respiratory
experiment type: MULTIPLE
co-administered: ALBUTEROL
ALBUTEROL
 IPRATROPIUM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
168 ug 3 times / day steady, respiratory
Highest studied dose
Dose: 168 ug, 3 times / day
Route: respiratory
Route: steady
Dose: 168 ug, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751529/
unhealthy, 18 - 75 years
n = 96
Health Status: unhealthy
Condition: perennial allergic rhinitis
Age Group: 18 - 75 years
Sex: M+F
Population Size: 96
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751529/
Disc. AE: Nasal disorder NOS, Nasal dryness...
AEs leading to
discontinuation/dose reduction:
Nasal disorder NOS (17%)
Nasal dryness (2%)
Epistaxis (2%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751529/
168 ug 3 times / day steady, respiratory
Highest studied dose
Dose: 168 ug, 3 times / day
Route: respiratory
Route: steady
Dose: 168 ug, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15702820/
unhealthy, 2 - 5 years
n = 43
Health Status: unhealthy
Condition: common colds
Age Group: 2 - 5 years
Sex: M+F
Population Size: 43
Sources:
https://pubmed.ncbi.nlm.nih.gov/15702820/
Disc. AE: Epistaxis...
AEs leading to
discontinuation/dose reduction:
Epistaxis (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/15702820/
84 ug 3 times / day steady, respiratory
Highest studied dose
Dose: 84 ug, 3 times / day
Route: respiratory
Route: steady
Dose: 84 ug, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15702820/
unhealthy, 2 - 5 years
n = 187
Health Status: unhealthy
Condition: allergies
Age Group: 2 - 5 years
Sex: M+F
Population Size: 187
Sources:
https://pubmed.ncbi.nlm.nih.gov/15702820/
Disc. AE: Epistaxis, Upper respiratory tract infection...
AEs leading to
discontinuation/dose reduction:
Epistaxis (1 patient)
Upper respiratory tract infection (1 patient)
Ear infection (1 patient)
Exacerbation of asthma (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/15702820/
200 ug single, respiratory
Highest studied dose
Dose: 200 ug
Route: respiratory
Route: single
Dose: 200 ug
Sources:
https://pubmed.ncbi.nlm.nih.gov/2150695/
unhealthy, mean 40.7 years
n = 20
Health Status: unhealthy
Condition: stable chronic asthma
Age Group: mean 40.7 years
Sex: M+F
Population Size: 20
Sources:
https://pubmed.ncbi.nlm.nih.gov/2150695/
Disc. AE: Nausea and vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea and vomiting (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/2150695/
42 ug 1 times / day steady, respiratory
Recommended
Dose: 42 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 42 ug, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751528/
unhealthy, mean 42.6 years
n = 99
Health Status: unhealthy
Condition: rhinorrhea
Age Group: mean 42.6 years
Sex: M+F
Population Size: 99
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751528/
Other AEs: Nasal disorder NOS...
Other AEs:
Nasal disorder NOS (19 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751528/
AEs

AEs

AESignificanceDosePopulation
Nasal disorder NOS 17%
Disc. AE
168 ug 3 times / day steady, respiratory
Highest studied dose
Dose: 168 ug, 3 times / day
Route: respiratory
Route: steady
Dose: 168 ug, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751529/
unhealthy, 18 - 75 years
n = 96
Health Status: unhealthy
Condition: perennial allergic rhinitis
Age Group: 18 - 75 years
Sex: M+F
Population Size: 96
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751529/
Epistaxis 2%
Disc. AE
168 ug 3 times / day steady, respiratory
Highest studied dose
Dose: 168 ug, 3 times / day
Route: respiratory
Route: steady
Dose: 168 ug, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751529/
unhealthy, 18 - 75 years
n = 96
Health Status: unhealthy
Condition: perennial allergic rhinitis
Age Group: 18 - 75 years
Sex: M+F
Population Size: 96
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751529/
Nasal dryness 2%
Disc. AE
168 ug 3 times / day steady, respiratory
Highest studied dose
Dose: 168 ug, 3 times / day
Route: respiratory
Route: steady
Dose: 168 ug, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751529/
unhealthy, 18 - 75 years
n = 96
Health Status: unhealthy
Condition: perennial allergic rhinitis
Age Group: 18 - 75 years
Sex: M+F
Population Size: 96
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751529/
Epistaxis 1 patient
Disc. AE
168 ug 3 times / day steady, respiratory
Highest studied dose
Dose: 168 ug, 3 times / day
Route: respiratory
Route: steady
Dose: 168 ug, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15702820/
unhealthy, 2 - 5 years
n = 43
Health Status: unhealthy
Condition: common colds
Age Group: 2 - 5 years
Sex: M+F
Population Size: 43
Sources:
https://pubmed.ncbi.nlm.nih.gov/15702820/
Ear infection 1 patient
Disc. AE
84 ug 3 times / day steady, respiratory
Highest studied dose
Dose: 84 ug, 3 times / day
Route: respiratory
Route: steady
Dose: 84 ug, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15702820/
unhealthy, 2 - 5 years
n = 187
Health Status: unhealthy
Condition: allergies
Age Group: 2 - 5 years
Sex: M+F
Population Size: 187
Sources:
https://pubmed.ncbi.nlm.nih.gov/15702820/
Epistaxis 1 patient
Disc. AE
84 ug 3 times / day steady, respiratory
Highest studied dose
Dose: 84 ug, 3 times / day
Route: respiratory
Route: steady
Dose: 84 ug, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15702820/
unhealthy, 2 - 5 years
n = 187
Health Status: unhealthy
Condition: allergies
Age Group: 2 - 5 years
Sex: M+F
Population Size: 187
Sources:
https://pubmed.ncbi.nlm.nih.gov/15702820/
Exacerbation of asthma 1 patient
Disc. AE
84 ug 3 times / day steady, respiratory
Highest studied dose
Dose: 84 ug, 3 times / day
Route: respiratory
Route: steady
Dose: 84 ug, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15702820/
unhealthy, 2 - 5 years
n = 187
Health Status: unhealthy
Condition: allergies
Age Group: 2 - 5 years
Sex: M+F
Population Size: 187
Sources:
https://pubmed.ncbi.nlm.nih.gov/15702820/
Upper respiratory tract infection 1 patient
Disc. AE
84 ug 3 times / day steady, respiratory
Highest studied dose
Dose: 84 ug, 3 times / day
Route: respiratory
Route: steady
Dose: 84 ug, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15702820/
unhealthy, 2 - 5 years
n = 187
Health Status: unhealthy
Condition: allergies
Age Group: 2 - 5 years
Sex: M+F
Population Size: 187
Sources:
https://pubmed.ncbi.nlm.nih.gov/15702820/
Nausea and vomiting 1 patient
Disc. AE
200 ug single, respiratory
Highest studied dose
Dose: 200 ug
Route: respiratory
Route: single
Dose: 200 ug
Sources:
https://pubmed.ncbi.nlm.nih.gov/2150695/
unhealthy, mean 40.7 years
n = 20
Health Status: unhealthy
Condition: stable chronic asthma
Age Group: mean 40.7 years
Sex: M+F
Population Size: 20
Sources:
https://pubmed.ncbi.nlm.nih.gov/2150695/
Nasal disorder NOS 19 patients
42 ug 1 times / day steady, respiratory
Recommended
Dose: 42 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 42 ug, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751528/
unhealthy, mean 42.6 years
n = 99
Health Status: unhealthy
Condition: rhinorrhea
Age Group: mean 42.6 years
Sex: M+F
Population Size: 99
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751528/
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
OCT1
512

OCT2
647

OCT3
150

MATE1
306

MATE2
263
OCTN1
47

OCTN2
50

OCT1
327

OCT2
355

OCT3
80

MATE1
135

MATE2
96
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
OCT1
543
 yes [IC50 17.4 uM]
OCT3
150
 yes [IC50 2.5 uM]
OCT2
648
 yes [IC50 3.6 uM]
MATE1
308
 yes [IC50 30.5 uM]
MATE2
263
 yes [IC50 62.8 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
MATE1
135
 strong
MATE2
96
 strong
OCT1
327
 strong
OCT2
355
 strong
OCT3
80
 strong
OCTN1
47
 yes
OCTN2
50
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
KeyOrganics
KS-5051
Pharmeks
PHAR218016
ZINC
ZINC000013782937
http://zinc15.docking.org/substances/ZINC000013782937
PubMed

PubMed

TitleDatePubMed
Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants.
2001
Impact of patient characteristics on the risk of influenza/ILI-related complications.
2001
[Significance of bronchospasm in the development of bronchial obstruction in exogenous allergic alveolitis].
2001
[Effect of ipratropium bromide on histamine-induced bronchoconstriction in subjects with chronic airway obstruction].
2001
An economic overview of chronic obstructive pulmonary disease.
2001
Inhaled short-acting beta2-agonists versus ipratropium for acute exacerbations of chronic obstructive pulmonary disease.
2001
Is exercise tolerance limited by the heart or the lungs?
2001 Apr
Standard dose of inhaled albuterol significantly increases QT dispersion compared to low dose of albuterol plus ipratropium bromide therapy in moderate to severe acute asthma attacks in children.
2001 Dec
Effect of ipratropium bromide on airway and pulmonary muscarinic receptors in a rat model of chronic obstructive pulmonary disease.
2001 Jan
Inhaled anticholinergic therapy: applied pharmacology and interesting developments.
2001 Jan
Regular versus as-needed short-acting inhaled beta-agonist therapy for chronic obstructive pulmonary disease.
2001 Jan
The impact of combined inhaled bronchodilator therapy in the treatment of COPD.
2001 Jan
Pharmacokinetics and tissue distribution of the anticholinergics tiotropium and ipratropium in the rat and dog.
2001 Jul
Effectiveness of salmeterol versus ipratropium bromide on exertional dyspnoea in COPD.
2001 Jun
A retrospective study of risk factors for repeated admissions for asthma in a rural/suburban university hospital.
2001 May
Effects of inhalation of albuterol sulphate, ipratroprium bromide and frusemide on breathing mechanics and gas exchange in healthy exercising horses.
2001 May
In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium : a 3-week, randomized, double-blind, within-patient, multicenter study.
2001 May
Towards evidence based medicine for paediatricians.
2001 Nov
Lower arrythmogenic risk of low dose albuterol plus ipratropium.
2001 Oct
[RC-Cornet(R) improves the bronchodilating effect of Ipratropiumbromide (Atrovent(R)) inhalation in COPD-patients].
2001 Oct
Ipratropium bromide hydrofluoroalkane inhalation aerosol is safe and effective in patients with COPD.
2001 Oct
Alternative methods for assessing bronchodilator reversibility in chronic obstructive pulmonary disease.
2001 Sep
Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease.
2001 Sep 1
Cold-induced rhinitis in skiers--clinical aspects and treatment with ipratropium bromide nasal spray: a randomized controlled trial.
2001 Sep-Oct
[Asthma follow-up after treatment of status asthmaticus in ICU Pneumonology Department in Warsaw Medical University].
2002
Prevention and treatment of respiratory syncytial virus bronchiolitis and postbronchiolitic wheezing.
2002
Anticholinergic drugs for wheeze in children under the age of two years.
2002
Differential response of wheezes and ruttles to anticholinergics.
2002 Apr
Hospitalizations and mortality in the Lung Health Study.
2002 Aug 1
24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139].
2002 Aug 5
Clinical review: severe asthma.
2002 Feb
Hospital management of children with acute asthma exacerbations in Kuwait: adherence to international guidelines.
2002 Jul-Sep
Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial.
2002 Mar 1
Patents

Patents

JP2002541233A
400
JP2006517213A
3
JP2010184937A
3
US6632842
3

Sample Use Guides

In Vivo Use Guide
The usual starting dose of ATROVENT® HFA is two inhalations four times a day. Patients may take additional inhalations as required; however, the total number of inhalations should not exceed 12 in 24 hours.
Route of Administration: Oral
In Vitro Use Guide
Ba 679 BR, atropine, and ipratropium bromide inhibited electrical field stimulation (EFS)-induced contraction with IC50 values of 0.17, 0.74, and 0.58 nM, respectively, in guinea pig trachea. Ba 679 BR had a slower onset and longer duration of action than atropine or ipratropium bromide (the times required to attain 50% of the maximum response were 34.8, 3.8, and 7.6 min, respectively, and the times required for 50% recovery of the response were 540, 31.6, and 81.2 min, respectively).
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:38:39 UTC 2023
Edited
by admin
on Fri Dec 15 16:38:39 UTC 2023
Record UNII
GR88G0I6UL
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
IPRATROPIUM
VANDF   WHO-DD  
Common Name English
IPRATROPIUM ION
Common Name English
Ipratropium [WHO-DD]
Common Name English
IPRATROPIUM [VANDF]
Common Name English
IPRATROPIUM CATION
Common Name English
8-AZONIABICYCLO(3.2.1)OCTANE, 3-(3-HYDROXY-1-OXO-2-PHENYLPROPOXY)-8-METHYL-8-(1-METHYLETHYL)-, (3-ENDO,8-SYN)
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29704
Created by admin on Fri Dec 15 16:38:39 UTC 2023 , Edited by admin on Fri Dec 15 16:38:39 UTC 2023
NDF-RT N0000175574
Created by admin on Fri Dec 15 16:38:39 UTC 2023 , Edited by admin on Fri Dec 15 16:38:39 UTC 2023
WHO-ATC R01AX03
Created by admin on Fri Dec 15 16:38:39 UTC 2023 , Edited by admin on Fri Dec 15 16:38:39 UTC 2023
NDF-RT N0000175370
Created by admin on Fri Dec 15 16:38:39 UTC 2023 , Edited by admin on Fri Dec 15 16:38:39 UTC 2023
LIVERTOX NBK548667
Created by admin on Fri Dec 15 16:38:39 UTC 2023 , Edited by admin on Fri Dec 15 16:38:39 UTC 2023
NCI_THESAURUS C319
Created by admin on Fri Dec 15 16:38:39 UTC 2023 , Edited by admin on Fri Dec 15 16:38:39 UTC 2023
WHO-ATC R03BB01
Created by admin on Fri Dec 15 16:38:39 UTC 2023 , Edited by admin on Fri Dec 15 16:38:39 UTC 2023
WHO-ATC R03AL02
Created by admin on Fri Dec 15 16:38:39 UTC 2023 , Edited by admin on Fri Dec 15 16:38:39 UTC 2023
WHO-ATC R03AL01
Created by admin on Fri Dec 15 16:38:39 UTC 2023 , Edited by admin on Fri Dec 15 16:38:39 UTC 2023
Code System Code Type Description
WIKIPEDIA
Ipratropium
Created by admin on Fri Dec 15 16:38:39 UTC 2023 , Edited by admin on Fri Dec 15 16:38:39 UTC 2023
PRIMARY
MESH
D009241
Created by admin on Fri Dec 15 16:38:39 UTC 2023 , Edited by admin on Fri Dec 15 16:38:39 UTC 2023
PRIMARY
RXCUI
7213
Created by admin on Fri Dec 15 16:38:39 UTC 2023 , Edited by admin on Fri Dec 15 16:38:39 UTC 2023
ALTERNATIVE
NCI_THESAURUS
C61794
Created by admin on Fri Dec 15 16:38:39 UTC 2023 , Edited by admin on Fri Dec 15 16:38:39 UTC 2023
PRIMARY
DRUG CENTRAL
1475
Created by admin on Fri Dec 15 16:38:39 UTC 2023 , Edited by admin on Fri Dec 15 16:38:39 UTC 2023
PRIMARY
CAS
60205-81-4
Created by admin on Fri Dec 15 16:38:39 UTC 2023 , Edited by admin on Fri Dec 15 16:38:39 UTC 2023
PRIMARY
CHEBI
5956
Created by admin on Fri Dec 15 16:38:39 UTC 2023 , Edited by admin on Fri Dec 15 16:38:39 UTC 2023
PRIMARY
IUPHAR
325
Created by admin on Fri Dec 15 16:38:39 UTC 2023 , Edited by admin on Fri Dec 15 16:38:39 UTC 2023
PRIMARY
DAILYMED
GR88G0I6UL
Created by admin on Fri Dec 15 16:38:39 UTC 2023 , Edited by admin on Fri Dec 15 16:38:39 UTC 2023
PRIMARY
SMS_ID
100000091672
Created by admin on Fri Dec 15 16:38:39 UTC 2023 , Edited by admin on Fri Dec 15 16:38:39 UTC 2023
PRIMARY
EVMPD
SUB02767MIG
Created by admin on Fri Dec 15 16:38:39 UTC 2023 , Edited by admin on Fri Dec 15 16:38:39 UTC 2023
PRIMARY
DRUG BANK
DB00332
Created by admin on Fri Dec 15 16:38:39 UTC 2023 , Edited by admin on Fri Dec 15 16:38:39 UTC 2023
PRIMARY
EPA CompTox
DTXSID9048437
Created by admin on Fri Dec 15 16:38:39 UTC 2023 , Edited by admin on Fri Dec 15 16:38:39 UTC 2023
PRIMARY
LACTMED
Ipratropium
Created by admin on Fri Dec 15 16:38:39 UTC 2023 , Edited by admin on Fri Dec 15 16:38:39 UTC 2023
PRIMARY
RXCUI
1546373
Created by admin on Fri Dec 15 16:38:39 UTC 2023 , Edited by admin on Fri Dec 15 16:38:39 UTC 2023
PRIMARY
FDA UNII
GR88G0I6UL
Created by admin on Fri Dec 15 16:38:39 UTC 2023 , Edited by admin on Fri Dec 15 16:38:39 UTC 2023
PRIMARY
Related Record Type Details
Structure of IPRATROPIUM BROMIDE
SALT/SOLVATE -> PARENT
Structure of IPRATROPIUM BROMIDE ANHYDROUS
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of N-ISOPROPYL-N-METHYL NORTROPINE
METABOLITE -> PARENT
Related Record Type Details
Structure of IPRATROPIUM
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966